These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 35469709)
1. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. Perrone-Filardi P; Paolillo S; Agostoni P; Basile C; Basso C; Barillà F; Correale M; Curcio A; Mancone M; Merlo M; Metra M; Muscoli S; Nodari S; Palazzuoli A; Pedrinelli R; Pontremoli R; Senni M; Volpe M; Indolfi C; Sinagra G Eur J Intern Med; 2022 Aug; 102():8-16. PubMed ID: 35469709 [TBL] [Abstract][Full Text] [Related]
3. [Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials]. Filardi PP; Paolillo S; Indolfi C; Agostoni P; Basso C; Barillà F; Correale M; Curcio A; Mancone M; Merlo M; Metra M; Muscoli S; Nodari S; Palazzuoli A; Pedrinelli R; Pontremoli R; Senni M; Volpe M; Sinagra G G Ital Cardiol (Rome); 2022 Mar; 23(3):217-228. PubMed ID: 35343504 [TBL] [Abstract][Full Text] [Related]
4. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure. Marques da Silva P; Aguiar C Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335 [TBL] [Abstract][Full Text] [Related]
6. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure]. Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045 [TBL] [Abstract][Full Text] [Related]
7. [Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system blockade in heart failure patients - Part II: Mechanistic effects of sacubitril/valsartan, placement in current guidelines and use in clinical practice]. Filardi PP; Indolfi C; Paolillo S; Agostoni P; Basso C; Barillà F; Correale M; Curcio A; Mancone M; Merlo M; Metra M; Muscoli S; Nodari S; Palazzuoli A; Pedrinelli R; Pontremoli R; Senni M; Volpe M; Sinagra G G Ital Cardiol (Rome); 2022 Apr; 23(4):299-308. PubMed ID: 35343482 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Solomon SD; Braunwald E; J Am Coll Cardiol; 2023 Jul; 82(1):1-12. PubMed ID: 37212758 [TBL] [Abstract][Full Text] [Related]
9. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. Lillyblad MP Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499 [TBL] [Abstract][Full Text] [Related]
10. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction. Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065 [TBL] [Abstract][Full Text] [Related]
11. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. Docherty KF; Vaduganathan M; Solomon SD; McMurray JJV JACC Heart Fail; 2020 Oct; 8(10):800-810. PubMed ID: 33004114 [TBL] [Abstract][Full Text] [Related]
12. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan. Liu RC Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980 [TBL] [Abstract][Full Text] [Related]
13. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374 [TBL] [Abstract][Full Text] [Related]
14. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
15. Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. Iovanovici DC; Bungau SG; Vesa CM; Moisi M; Babes EE; Tit DM; Horvath T; Behl T; Rus M Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232632 [TBL] [Abstract][Full Text] [Related]
16. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR; JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839 [TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction. Kuno T; Ueyama H; Fujisaki T; Briasouli A; Takagi H; Briasoulis A Am J Cardiol; 2020 Apr; 125(8):1187-1193. PubMed ID: 32081366 [TBL] [Abstract][Full Text] [Related]
18. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956 [TBL] [Abstract][Full Text] [Related]